Health Care M&A Weekly Deals, The Week Ending September 29, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price TRPharm License to FP-001 program N/A Geom Therapeutics, Inc. License to BLI program N/A Casebia Therapeutics Collaboration on gene-edited Tregs N/A Home Health Care & Hospice... Read More »
Stat(s) of the Week: 2017 Deal Volume Change, by Sector
If you thought 2017 has been slow for mergers and acquisitions, you must focus on the Home Health & Hospice or Pharmaceutical sectors. Those two top the list for underperforming sectors through September 27, 2017, compared with the same time last year. If you’re in Biotechnology, however, you’re not getting much sleep. We pulled data for the years 2016 and 2017, each set through September 27, just to see which sectors are up, and which are down. Overall, deal volume is 8% ahead of the same time last year, when the presidential election was raging. So far this year, we’ve recorded 1,105 transactions, compared with 1.024 in the same period in 2016. The... Read More »Health Care M&A Weekly Deals, The Week Ending September 22, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Mitobridge, Inc. License to NAD+ intellectual property N/A Pluriomics B.V. Axiogenesis AG N/A InDevR, Inc. License to monoclonal antibodies N/A STEMCELL Technologies Inc. License to EpiX™ technology N/A... Read More »Stat of the Week: M&A in 2017
Since July, we’ve seen several headlines in the trades regarding deal making activity in various healthcare sectors. We’ve also attended several conferences and forums focused on healthcare deal making. What we hear at those conferences is usually closer to the truth than what we’ve read. It may be all about the methodology, but here’s our take on overall deal volume and value in 2017, through August 31. Last year, 2016, set a new record in overall deal volume among the 13 sectors we track in our Deal Search Online database. The combined total of deals for last year stands at 1,568, only 2% greater than the 1,530 announced in 2015. This year could be even better, if... Read More »
August Marks the Return of the Big Deals
The dog days of summer weren’t really all that hot, here in the Northeast. Neither was August’s deal volume. Although it’s preliminary data, the 102 deals posted in August equalled the total in July. Compared with the same month in 2016, that represents a 22% slide in deal volume. But don’t fret, deal-meisters. We saw several billion-dollar deals last month, which lifted August 2017’s spending to $22.3 billion. That’s 156% higher than the previous month, and just 1% below the $22.6 billion recorded a year ago. Once again, the Biotechnology sector was the big money-maker. Deal volume was up 30%, year over year, to a modest 13 deals. The largest deal announced in August was Gilead Sciences’... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
